Cargando…

Clinical and Pathologic Complete Response to Gefitinib in a Patient with SqCLC Harboring EGFR p.E746_S752delinsV Mutation

Development of targeted therapies for squamous cell lung cancer (SqCLC) is currently limited by the prevalence of activating mutations and their predicting power of treatment efficacy. In the present study, we describe a case of treatment-naïve stage IIIB SqCLC that harbored a rare epidermal growth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhuang, Weitao, Zhang, Chao, Tang, Yong, Tian, Dan, Lan, Zihua, Zeng, Cheng, Qiao, Guibin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450156/ https://www.ncbi.nlm.nih.gov/pubmed/34552336 http://dx.doi.org/10.2147/OTT.S328839

Ejemplares similares

ERAP2 Is Associated With Immune Infiltration and Predicts Favorable Prognosis in SqCLC
por: Yang, Zhenlin, et al.
Publicado: (2021)

The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports
por: Meng, Yamin, et al.
Publicado: (2023)

Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease
por: Okawa, Sachi, et al.
Publicado: (2021)

Case Report: Afatinib Sensitivity in Rare EGFR E746_L747delinsIP Mutated LUAD With Peritoneal Metastases
por: Zhang, Lili, et al.
Publicado: (2022)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
por: Kuwata, Taiji, et al.
Publicado: (2016)

Efficacy of osimertinib in a metastatic lung adenocarcinoma patient harboring somatic EGFR delL747_S752 and germline BIM deletion polymorphism: a case report and literature review
por: Zheng, Wenyu, et al.
Publicado: (2022)

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification
por: Wang, Xiaomeng, et al.
Publicado: (2021)

Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report
por: Fang, Yueh‐Fu, et al.
Publicado: (2021)

Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations
por: Jiang, Xuhong, et al.
Publicado: (2020)

746 Nurse Driven Fluid Resuscitation in the Burn Center
por: Werthman, Emily H, et al.
Publicado: (2022)

752. Management of 20 Patients Diagnosed with Posaconazole-Induced Pseudohyperaldosteronism
por: Gintjee, Thomas J, et al.
Publicado: (2020)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
por: Liang, Wenhua, et al.
Publicado: (2014)

Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib
por: Xu, Wei, et al.
Publicado: (2015)

Bacteriological Study of Stools of 746 Clinical Cholera Cases in Calcutta
por: Maitra, G. C., et al.
Publicado: (1925)

752 Assessment of Aminoglycoside Dosing at a Large Academic Medical Center
por: Ghamrawi, Riane, et al.
Publicado: (2014)

752. Costs Attributable to Clostridioides difficile Infection in the Presence of Differential Mortality
por: Sahrmann, John, et al.
Publicado: (2021)

Lung adenocarcinoma organoids harboring EGFR 19Del and L643V double mutations respond to osimertinib and gefitinib: A case report
por: Bie, Yanan, et al.
Publicado: (2021)

In Vivo Efficacy of SQ109 against Leishmania donovani, Trypanosoma spp. and Toxoplasma gondii and In Vitro Activity of SQ109 Metabolites
por: Baek, Kyung-Hwa, et al.
Publicado: (2022)

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
por: Yang, Chih-Jen, et al.
Publicado: (2017)

Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy
por: Wang, Yanyan, et al.
Publicado: (2023)

752. Geographic Analysis of Latent Tuberculosis Screening: A Health System Approach
por: Bonnewell, John, et al.
Publicado: (2018)

The importance of regulation (EU) 2017/746 for quality control in medical laboratories
por: Ialongo, Cristiano, et al.
Publicado: (2021)

Gefitinib Analogue V1801 Induces Apoptosis of T790M EGFR-Harboring Lung Cancer Cells by Up-Regulation of the BH-3 Only Protein Noxa
por: Zhang, Bo, et al.
Publicado: (2012)

Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports
por: Chonan, Masashi, et al.
Publicado: (2016)

Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
por: Yang, Hua, et al.
Publicado: (2016)

752. Timing of Antibiotics Administration in Emergency Department and Mortality in Sepsis by Sepsis-3 Definition
por: Seok, Hyeri, et al.
Publicado: (2019)

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
por: Bailey, Matthew H., et al.
Publicado: (2020)

Draft Genome Sequence of a Ketoprofen Degrader, Rhodococcus erythropolis IEGM 746
por: Ivshina, Irina B., et al.
Publicado: (2022)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity
por: Jun, Sei-Yong, et al.
Publicado: (2022)

Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions
por: Kato, Yuka, et al.
Publicado: (2018)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells
por: Cruz Da Silva, Elisabete, et al.
Publicado: (2021)

ClC‐c regulates the proliferation of intestinal stem cells via the EGFR signalling pathway in Drosophila
por: Huang, Jinping, et al.
Publicado: (2021)

Investigation of an EHV-1 Outbreak in the United States Caused by a New H(752) Genotype
por: Pusterla, Nicola, et al.
Publicado: (2021)

Cysteine Accessibility in ClC-0 Supports Conservation of the ClC Intracellular Vestibule
por: Engh, Anita M., et al.
Publicado: (2005)

SUN-746 Thyroid Hormone Receptor Alpha Sumoylation Is Important for the Development of Adipose Tissue
por: Abe, Kiyomi, et al.
Publicado: (2020)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

ClC chloride channels
por: Mindell, Joe, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_esucb2v6nqo6dc1pptgmbtcqjl